Giampaolo Bianchini

26PUBLICATIONS
128CO-AUTHORS
ChemotherapyMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Dental therapeutics, pharmacology and toxicology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jul 31, 2026
TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.

|Jan 30, 2026
Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy.

Giulia Notini, Giampaolo Bianchini, José Manuel Pérez-García

|Jan 26, 2026
Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial.

Giampaolo Bianchini, Luca Malorni, Roberta Caputo

|Jul 21, 2025
Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer.

Luca Licata, Marco Mariani, Giulia Viale

|May 14, 2025
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.

Anna Amela Valsecchi, Simona Pisegna, Andrea Antonuzzo

|Mar 26, 2025
Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.

Funda Meric-Bernstam, Aditya Bardia, Paolo Bossi

Pageof 5

Frequent Collaborators

8 joint publications

Lucia Del Mastro

5 joint publications

Maurizio Callari

5 joint publications

Fabio Puglisi

5 joint publications

Lajos Pusztai